Long-term Intraocular Lens (IOL) Decentration and Tilt in Eyes With Pseudoexfoliation Syndrome (PES) Following Cataract Surgery
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03453827 |
|
Recruitment Status :
Completed
First Posted : March 5, 2018
Last Update Posted : March 8, 2018
|
Sponsor:
Hospital Hietzing
Information provided by (Responsible Party):
Kata Mihaltz, Hospital Hietzing
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
To evaluate long-term intraocular lens (IOL) decentration and tilt in eyes with pseudoexfoliation syndrome (PES) following cataract surgery using Visante anterior segment OCT and iTrace Visual Function Analyzer.
| Condition or disease | Intervention/treatment |
|---|---|
| Cataract Pseudoexfoliation Syndrome Pseudophakia | Other: no intervention |
64 eyes following cataract surgery from 2009 to 2012 were included, 34 eyes had PES, 30 eyes did not show PES. A standard phacoemulsification procedure followed by IOL implantation was performed and patients were followed 4-6 years after surgery (mean=69 months). Best corrected visual acuity (BCVA), intraocular pressure (IOP) and capsulorhexis size were measured. IOL tilt and IOL decentration were evaluated using Visante Omni anterior segment OCT (Carl Zeiss Jena GmBH, Germany). The iTrace VFA (Visual Function Analyzer, Topcon Medical Systems, Inc.) was used to measure internal, corneal and total optical aberrations.
| Study Type : | Observational |
| Actual Enrollment : | 37 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Retrospective |
| Official Title: | Assessment of Long-term Intraocular Lens (IOL) Decentration and Tilt in Eyes With Pseudoexfoliation Syndrome (PES) Following Cataract Surgery |
| Actual Study Start Date : | April 1, 2016 |
| Actual Primary Completion Date : | April 28, 2017 |
| Actual Study Completion Date : | April 28, 2017 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
PEX
Patients after Cataract surgery with PES
|
Other: no intervention
no intervention |
|
Control
Patients after Cataract surgery without PES
|
Other: no intervention
no intervention |
Primary Outcome Measures :
- IOL decentration [ Time Frame: 4-6 years after cataract surgery ]decentration of IOL is measured using Hoya iTrace
- IOL tilt [ Time Frame: 4-6 years after cataract surgery ]tilt of implanted IOL is measured using Hoya iTace
- IOL decentration [ Time Frame: 4-6 years after cataract surgery ]decentration of IOL is measured using Zeiss OCT
- IOL tilt [ Time Frame: 4-6 years after cataract surgery ]tilt of implanted IOL is measured using Zeiss OCT
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 125 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Sampling Method: | Probability Sample |
Study Population
Patients who underwent standard procedure cataract surgery with or without Pseudoexfoliation Syndrome.
Criteria
Inclusion Criteria:
- patients 4-6 years after standard cataract surgery
- pseudoexfoliation Syndrome (PES)
Exclusion Criteria:
- Diabetic retinopathy
- Age related macula Degeneration
- retinal bloodvessel disease
No Contacts or Locations Provided
| Responsible Party: | Kata Mihaltz, Oberarzt M.D. PhD FEBO, Hospital Hietzing |
| ClinicalTrials.gov Identifier: | NCT03453827 |
| Other Study ID Numbers: |
PEX Study |
| First Posted: | March 5, 2018 Key Record Dates |
| Last Update Posted: | March 8, 2018 |
| Last Verified: | March 2018 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Kata Mihaltz, Hospital Hietzing:
|
Pseudoexfoliation Syndrome Cataract Aberration IOL decentration IOL tilt |
Additional relevant MeSH terms:
|
Cataract Exfoliation Syndrome Syndrome Pseudophakia Disease |
Pathologic Processes Lens Diseases Eye Diseases Iris Diseases Uveal Diseases |

